12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vintafolide: Completed Phase IIb enrollment

Endocyte disclosed in its 2Q13 earnings that it completed enrollment in the open-label, international Phase IIb TARGET trial comparing 2.5 mg vintafolide given on days 1, 4, 8 and 11 as a single agent and in combination with docetaxel vs. docetaxel alone in about 180 patients. The trial...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >